Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy
暂无分享,去创建一个
A. Burroughs | P. Griffiths | V. Emery | S. Atabani | D. Thorburn | N. Rolando | M. Harber | R. Aldridge | J. O’Beirne | Colette Smith | R. Milne | C. Atkinson | M. Rodríguez-Perálvarez | R. Aldridge | A. O'Riordan | G. Jones | P. Griffiths | C. Smith | J. O’Beirne | R. Milne
[1] V. Emery,et al. Cytomegalovirus quantification: where to next in optimising patient management? , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[2] A. Davenport,et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial , 2011, The Lancet.
[3] D. Abramowicz,et al. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[4] O. Hes,et al. Intragraft Cytomegalovirus Infection: A Randomized Trial of Valacyclovir Prophylaxis versus Pre-Emptive Therapy in Renal Transplant Recipients , 2010, Antiviral therapy.
[5] P. Klenerman,et al. Polyfunctional Cytomegalovirus‐Specific CD4+ and pp65 CD8+ T Cells Protect Against High‐Level Replication After Liver Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] P. Klenerman,et al. Functional Impairment of Cytomegalovirus Specific CD8 T Cells Predicts High‐Level Replication After Renal Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] M. Schnitzler,et al. Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] A. Burroughs,et al. Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis , 2006, Proceedings of the Royal Society B: Biological Sciences.
[9] H. Schäfers,et al. Differences in CMV‐Specific T‐Cell Levels and Long‐Term Susceptibility to CMV Infection after Kidney, Heart and Lung Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] A. Bertoletti,et al. Evolution of hepatitis B virus during primary infection in humans: transient generation of cytotoxic T-cell mutants. , 2004, Gastroenterology.
[11] Guy Boivin,et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. , 2002, The Journal of infectious diseases.
[12] Andrew K Burroughs,et al. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. , 2002, The Journal of infectious diseases.
[13] P. Griffiths,et al. Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] J. Preiksaitis,et al. The risk of transfusion‐acquired CMV infection in seronegative solid‐organ transplant recipients receiving non‐WBC‐reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center , 2002, Transfusion.
[15] K. Borner,et al. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. , 2001, Transplantation proceedings.
[16] A. Meyerhans,et al. LEVELS OF VIRUS-SPECIFIC CD4 T CELLS CORRELATE WITH CYTOMEGALOVIRUS CONTROL AND PREDICT VIRUS-INDUCED DISEASE AFTER RENAL TRANSPLANTATION1 , 2001, Transplantation.
[17] D. Mclone. The Risk , 2001, Pediatric Neurosurgery.
[18] A. Limaye,et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants , 2000, The Lancet.
[19] C. Sabin,et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation , 2000, The Lancet.
[20] Vincent C. Emery,et al. The Dynamics of Human Cytomegalovirus Replication in Vivo , 1999, The Journal of experimental medicine.
[21] J. Gómez-Moreno,et al. Infection in organ-transplant recipients. , 1998, The New England journal of medicine.
[22] C. Sabin,et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. , 1997, The Journal of infectious diseases.
[23] C. Sabin,et al. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation , 1997, Journal of medical virology.
[24] Angela M Caliendo,et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. , 2010, Transplantation.
[25] A. Limaye,et al. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. , 2008, The Journal of infectious diseases.
[26] A. Burroughs,et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. , 2005, Journal of Infectious Diseases.